We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 18

Pharmacies told not to sell unauthorized natural health products
  • Gowling WLG
  • Canada
  • June 9 2010

The National Association of Pharmacy Regulatory Authorities (NAPRA), a voluntary association of provincial and territorial pharmacy regulatory bodies, issued a position statement last month encouraging member associations and pharmacists not to sell natural health products that have not been licensed with a Drug Identification Number (DIN), or a Natural Product Number (NPN).


Second phase of Alberta's pharmaceutical strategy aims to reduce drug costs, improve access to new drugs and expand the role of pharmacists
  • Gowling WLG
  • Canada
  • November 2 2009

On October 20, 2009, the Alberta Government released the second phase of the Alberta Pharmaceutical Strategy which indicates that the Government will reduce generic drug prices - the Government states it will reduce the price of new generic drugs from 75 percent of the brand name drug to 45 and announces that its discussions with pharmacists and pharmacies regarding the price reduction will begin this month.


Canadian Pharmaceutical Technologies International v. Canada
  • Gowling WLG
  • Canada
  • May 4 2009

The Court upheld the decision of Health Canada that the applicant's product was indeed a "drug in dosage form" and thus was subject to the provisions of the Food and Drugs Act and Regulations.


Increased competition for generic drugs could save Canadians $800 million a year
  • Gowling WLG
  • Canada
  • November 26 2008

The Competition Bureau has released a new study of the generic drug industry, Benefiting from Generic Drug Competition in Canada: The Way Forward, that proposes a number of changes to increase competition in the supply of generic drugs.


OFT holds fire on new drug distribution model
  • Gowling WLG
  • United Kingdom
  • December 14 2007

This new trend has upset the old order.


Competition Bureau study finds generic Canadians are paying too much for generic drugs
  • Gowling WLG
  • Canada
  • November 16 2007

The Competition Bureau released its Generic Drug Study on October 29, 2007.


New regulations respecting benefits and promotional allowances in Québec
  • Gowling WLG
  • Canada
  • November 16 2007

The Government of Québec has introduced new regulations under the Act Respecting Prescription Drug Insurance governing the rebates and other benefits offered by drug manufacturers to pharmacists.


Pharmacy association defends generic drug prices
  • Gowling WLG
  • Canada
  • November 16 2007

The Canadian Competition Bureau recently released a report on the price of generic drugs in Canada and indicated therein that although many generic manufacturers offer up to 40 rebates on generic drugs, pharmacies are not passing these rebates on to consumers.


Beverley Moore
  • Gowling WLG